Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5‐year results from the randomized placebo‐controlled TRANSFIGURE study* - Concepedia

Concepedia

Publication | Closed Access

Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5‐year results from the randomized placebo‐controlled TRANSFIGURE study*

70

Citations

25

References

2020

Year

Kristian Reich, John Sullivan, Petr Arenberger, S. Jazayeri, Ulrich Mrowietz, Matthias Augustin, Boni E. Elewski, R. You, P. Regnault, Jennifer Frueh

British Journal of Dermatology

Abstract

Secukinumab demonstrated strong and clinically meaningful efficacy for up to 2·5 years in nail psoriasis, with significant sustained QoL improvements and a favourable safety profile.

References

	Year	Citations

Page 1